Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Vanda Pharmaceuticals (VNDA) PT Lowered to $21 at Oppenheimer
February 14, 2019 8:10 AM ESTOppenheimer analyst Esther Rajavelu lowered the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $21.00 (from $29.00) while maintaining a Perform rating.
The analyst commented, "VNDA reported 4Q results that were higher than our estimates and provided 2019 guidance which came in below our (and... More
